Compare · OSUR vs RMD
OSUR vs RMD
Side-by-side comparison of OraSure Technologies Inc. (OSUR) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OSUR and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 129.6x OSUR ($262.8M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 1 for OSUR).
- RMD has more recent analyst coverage (25 ratings vs 5 for OSUR).
- Company
- OraSure Technologies Inc.
- ResMed Inc.
- Price
- $3.62-5.24%
- $239.08-1.35%
- Market cap
- $262.8M
- $34.07B
- 1M return
- +3.58%
- -
- 1Y return
- +19.87%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 9
- Recent ratings
- 5
- 25
OraSure Technologies Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. The company operates in two segments, Diagnostics and Molecular Solutions. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company's principal products include OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND services, a suite of genomic services. In addition, the company offers ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbime, and animal genetics markets. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest OSUR
- Director Boyd Steven Kyle was granted 4,797 shares, increasing direct ownership by 3% to 168,031 units (SEC Form 4)
- Director Kenny John P. covered exercise/tax liability with 5,116 shares, decreasing direct ownership by 2% to 204,598 units (SEC Form 4)
- SEC Form S-8 filed by OraSure Technologies Inc.
- SEC Form 10-Q filed by OraSure Technologies Inc.
- OraSure Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OraSure Announces Second Quarter 2026 Financial Results
- OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
- OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
- Director Boyd Steven Kyle was granted 3,666 shares, increasing direct ownership by 2% to 163,234 units (SEC Form 4)
- OraSure Technologies Inc. filed SEC Form 8-K: Other Events
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target